Low Testosterone Linked to Aggressive Prostate Cancer in Active Surveillance | MD Anderson Study

For men undergoing active surveillance for early-stage prostate cancer, a recent study suggests a surprising connection: lower testosterone levels may correlate with a higher risk of the cancer becoming more aggressive. Published this month in The Journal of Urology, the research, led by investigators at The University of Texas MD Anderson Cancer Center, challenges long-held assumptions about the role of testosterone in prostate cancer progression. The findings indicate that baseline testosterone measurements could become a valuable tool for clinicians in assessing risk and tailoring monitoring strategies for patients choosing to forego immediate treatment.

Active Surveillance and the Role of Hormones

Active surveillance is a widely accepted approach for men diagnosed with low-risk prostate cancer. It involves regular monitoring – typically including PSA blood tests, digital rectal exams and repeat biopsies – to track the cancer’s behavior. The goal is to avoid the potential side effects of immediate treatment, such as surgery or radiation, unless the cancer shows signs of becoming more threatening. Traditionally, it was believed that higher levels of testosterone fueled the growth of prostate cancer. This new research, whereas, suggests a more nuanced relationship.

The MD Anderson study found that men with lower testosterone levels at the start of active surveillance were 60% more likely to experience cancer progression to a more aggressive state over time. This doesn’t mean low testosterone causes progression, but rather that it appears to be associated with it. Researchers emphasize the need to understand how hormonal factors influence prostate cancer biology to refine surveillance strategies. Justin R. Gregg, M.D., associate professor of Urology and Health Disparities Research at MD Anderson and the study’s corresponding author, explained that identifying patients at higher risk of progression remains a significant challenge in managing early-stage prostate cancer.

Understanding Testosterone and Prostate Cancer

The relationship between testosterone and prostate cancer is complex. For many years, the prevailing theory was that testosterone directly stimulated the growth of prostate cancer cells. This led to the widespread use of androgen deprivation therapy (ADT) – treatments that lower testosterone levels – to leisurely cancer growth in men with advanced prostate cancer. However, the impact of testosterone on early-stage cancer has been less clear. Mayo Clinic explains that many prostate cancers are sensitive to testosterone, meaning the hormone can help cancer cells grow and multiply, but the interplay is not straightforward.

This new study adds another layer to this understanding. It suggests that low testosterone might create a more favorable environment for aggressive cancer cells to thrive, or that it could be a marker for other underlying biological factors that contribute to progression. It’s important to note that the study focused on men already enrolled in active surveillance, and the findings don’t necessarily apply to all men with prostate cancer.

Study Details and Limitations

The research involved a retrospective analysis of data from men with prostate cancer undergoing active surveillance at MD Anderson. Researchers examined the association between baseline testosterone levels and the risk of cancer progression, defined as upgrading to a more aggressive Gleason score or requiring definitive treatment. The study, detailed in Newswise, highlights the potential of testosterone as a clinical marker. However, it’s crucial to acknowledge the study’s limitations. As a retrospective study, it can only demonstrate an association, not causation. Other factors, such as age, race, family history, and genetic predispositions, could also play a role in cancer progression and were not fully accounted for in the analysis.

the study population was limited to patients at a single cancer center, which may not be representative of all men with prostate cancer. Additional research, including prospective studies with larger and more diverse populations, is needed to confirm these findings and to determine the optimal testosterone levels for men undergoing active surveillance.

What Does This Mean for Patients?

These findings do not warrant any immediate changes to current clinical practice. Men currently on active surveillance should continue to follow their doctor’s recommendations for monitoring and follow-up. However, the study does suggest that testosterone levels should be considered as part of a comprehensive risk assessment. Discussing testosterone levels with your urologist may become a more common part of the conversation surrounding active surveillance.

It’s also important to remember that active surveillance remains a safe and effective option for many men with low-risk prostate cancer. The goal is to avoid unnecessary treatment and its associated side effects. This research doesn’t suggest that low testosterone is a death sentence, but rather that it may be a signal to more closely monitor the cancer’s behavior.

The Path Forward: Refining Surveillance Strategies

The researchers at MD Anderson are continuing to investigate the role of hormones in prostate cancer progression. Future studies will focus on identifying the underlying mechanisms by which testosterone influences cancer biology and on developing more personalized surveillance strategies. MD Anderson’s research newsroom indicates that baseline testosterone may serve as a useful clinical marker to guide treatment and surveillance strategies.

The findings also highlight the importance of ongoing research into prostate cancer biomarkers – measurable indicators of cancer risk or progression. Identifying reliable biomarkers could help clinicians to more accurately predict which patients are likely to benefit from active surveillance and which patients may require more aggressive treatment. The process of refining surveillance strategies will likely involve clinical trials to test the effectiveness of different monitoring protocols based on testosterone levels and other biomarkers.

Looking ahead, clinicians will likely integrate testosterone level assessment into the broader risk stratification process for men on active surveillance, alongside established factors like Gleason score, PSA density, and clinical stage. This will allow for a more individualized approach to prostate cancer management, ensuring that patients receive the most appropriate care based on their specific risk profile.